Skip to main content

Functional Analysis of Schizophrenia Risk Gene RBM12

Periodic Reporting for period 1 - SZFunc (Functional Analysis of Schizophrenia Risk Gene RBM12)

Reporting period: 2018-09-01 to 2020-08-31

Schizophrenia is a devastating disease with substantial costs for society. Although the disease has been described for thousands of years, its biological basis is unknown and there are no biomarkers. Antipsychotic drugs alleviate only a subset of the symptoms and are thought to act through a single mechanism: blockade of the type 2 dopaminergic receptor. Our goal is to better understand the biology of the disease, setting the stage for the development of novel, more efficacious treatments.
"We have created ""knockout"" rbm12 zebrafish lines. We find that these lines show altered behavior at larval stages. We also have carried out an initial experiment to identify the RNAs with which rbm12, an RNA-binding protein, interacts."
We expect to carry out further experiments to understand the molecular interactions of rbm12 in the next year. Because truncation or RBM12 is strongly associated with schizophrenia, these results may lead to new insights into schizophrenia's biology.